• 1. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Recent Advances in the Study of 725228-44-4 and Decahydroisoquinolin-6-ol: A Comprehensive Research Brief

The chemical compound with the CAS number 725228-44-4, structurally related to decahydroisoquinolin-6-ol, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. The decahydroisoquinolin-6-ol scaffold is particularly noteworthy due to its presence in various bioactive molecules, making it a valuable target for drug discovery and development.

Recent studies have explored the synthetic pathways for 725228-44-4, highlighting novel catalytic methods that improve yield and selectivity. One study published in the Journal of Medicinal Chemistry demonstrated a streamlined approach to synthesizing decahydroisoquinolin-6-ol derivatives, which could facilitate the production of analogs for further biological testing. The researchers employed asymmetric hydrogenation techniques, achieving high enantiomeric purity, a critical factor for pharmaceutical applications.

In terms of biological activity, preliminary in vitro assays have shown that derivatives of decahydroisoquinolin-6-ol exhibit promising activity against central nervous system (CNS) targets. Specifically, these compounds have been investigated for their potential as modulators of GABA receptors, which are implicated in anxiety and epilepsy. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported that certain analogs of 725228-44-4 displayed nanomolar affinity for GABA-A receptors, suggesting their utility in developing novel anxiolytics or anticonvulsants.

Further investigations into the pharmacokinetic properties of decahydroisoquinolin-6-ol derivatives have revealed favorable absorption and distribution profiles. A recent preclinical study highlighted the compound's ability to cross the blood-brain barrier efficiently, a desirable trait for CNS-targeted therapies. Additionally, metabolic stability studies indicated that these compounds are resistant to rapid degradation, potentially allowing for less frequent dosing regimens in clinical settings.

Despite these promising findings, challenges remain in optimizing the safety and efficacy profiles of 725228-44-4 and its derivatives. Toxicity studies conducted in animal models have identified dose-dependent hepatotoxicity as a potential concern, necessitating further structural modifications to mitigate adverse effects. Researchers are currently exploring the introduction of polar functional groups to enhance solubility and reduce off-target interactions.

In conclusion, the ongoing research on 725228-44-4 and decahydroisoquinolin-6-ol underscores their potential as versatile scaffolds in medicinal chemistry. The recent advancements in synthesis and biological evaluation provide a solid foundation for future drug development efforts. However, comprehensive preclinical and clinical studies will be essential to fully realize their therapeutic potential. This brief serves as a timely update for researchers and industry professionals engaged in the exploration of these compounds.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)